PT - JOURNAL ARTICLE AU - Irsara, Christian AU - Egger, Alexander E. AU - Prokop, Wolfgang AU - Nairz, Manfred AU - Loacker, Lorin AU - Sahanic, Sabina AU - Sonnweber, Thomas AU - Mayer, Wolfgang AU - Schennach, Harald AU - Loeffler-Ragg, Judith AU - Bellmann-Weiler, Rosa AU - Tancevski, Ivan AU - Weiss, Günter AU - Anliker, Markus AU - Griesmacher, Andrea AU - Hoermann, Gregor TI - Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay AID - 10.1101/2020.11.27.20239590 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.27.20239590 4099 - http://medrxiv.org/content/early/2020/11/30/2020.11.27.20239590.short 4100 - http://medrxiv.org/content/early/2020/11/30/2020.11.27.20239590.full AB - Objectives Serological tests detect antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the ongoing coronavirus disease-19 (COVID-19) pandemic. Independent external clinical validation of performance characteristics is of paramount importance.Methods Four fully automated assays, Roche Elecsys Anti-SARS-CoV-2, Abbott SARS-CoV-2 IgG, Siemens SARS-CoV-2 total (COV2T) and SARS-CoV-2 IgG (COV2G) were evaluated using 350 pre-pandemic samples and 700 samples from 245 COVID-19 patients (158 hospitalized, 87 outpatients).Results All tests showed very high diagnostic specificity. Sensitivities in samples collected at least 14 days after disease onset were slightly lower than manufacturers’ claims for Roche (93.04%), Abbott (90.83%), and Siemens COV2T (90.26%), and distinctly lower for Siemens COV2G (78.76%). Concordantly negative results were enriched for immunocompromised patients. ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay. Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results.Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories. The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the company’s newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies. A combination of tests could be considered in clinical practice.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by the ethics committee of the Medical University of Innsbruck (ethics commission numbers: 1103/2020, 1167/2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSee section supplemental dataCIconfidence intervalCLIAchemiluminescence immunoassayCOIcut-off indexCOVID-19Coronavirus disease 2019ELISAenzyme-linked immunosorbent assayLFIAlateral flow immunoassayICUintensive care unitIgImmunoglobulinIQRinterquartile rangeROCreceiver operating characteristicRT-PCRreverse transcription polymerase chain reaction